Z-Screen makes combinatorial molecules, profiles their cell-state effects, and keeps every response tied to the recipe that produced it. The pilot is already one of the largest public combinatorial chemistry transcriptomic datasets. More investment can scale the loop to million-compound campaigns, richer cell models, and faster mechanism triage.
The current release is evidence that learn-in-a-loop at scale works: make chemistry, read cell state, learn the map, and feed the next campaign.
The chip is the throughput unit. More campaigns can mean more chips, more libraries, and more cell contexts rather than a bespoke automation build for every program.
Because each RNA profile remains attached to building-block provenance, the dataset becomes a reusable chemistry-to-biology map rather than a one-time hit list.
CRISPR-state matching does not prove target engagement. It does turn an unknown phenotypic hit into a prioritized, chemistry-addressable validation queue.
The platform story is broader than one disease area: combinatorial small molecules today, with a path toward richer image channels, more cell models, and partner-specific discovery maps.
The cards below are a fast read on what the pilot already observed: paired readouts, learnable chemistry, honest generalization tests, cross-cell transfer, and CRISPR-linked mechanism hypotheses. Click any card for details.
The pilot supports the platform thesis, but it was not designed to saturate the opportunity. Focused additional investment should be aimed at the bottlenecks the papers identify: larger chemistry coverage, richer paired readouts, prospective scaffold-hop tests, and matched-cell validation for mechanism hypotheses.
These draft manuscripts are circulated for feedback ahead of a bioRxiv submission. The full public dataset and analysis scripts are available on Zenodo for independent evaluation.